[1]杨雪,李楠,王海兵.不同剂量瑞舒伐他汀对中国人颈动脉粥样硬化斑块影响的Meta分析[J].第三军医大学学报,2016,38(03):233-237.
 Yang Xue,Li Nan,Wang Haibing.Effect of different doses of rosuvastatin on carotid atherosclerosis in Chinese patients: a Meta-analysis[J].J Third Mil Med Univ,2016,38(03):233-237.
点击复制

不同剂量瑞舒伐他汀对中国人颈动脉粥样硬化斑块影响的Meta分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第03期
页码:
233-237
栏目:
公共卫生与预防医学
出版日期:
2016-02-15

文章信息/Info

Title:
Effect of different doses of rosuvastatin on carotid atherosclerosis in Chinese patients: a Meta-analysis
作者:
杨雪李楠王海兵
解放军济南军区总医院干部病房四科;解放军401医院干部病房三科
Author(s):
Yang Xue Li Nan Wang Haibing

Forth Department of Cadre’s Ward, General Hospital of Jinan Military Command, Jinan, Shandong Province, 250031; Third Department of Cadre’s Ward, No. 401 Hospital of PLA, Qingdao, Shandong Province, 266071, China

关键词:
瑞舒伐他汀动脉粥样硬化颈动脉内膜厚度Meta分析
Keywords:
rosuvastatin atherosclerosis carotid artery intima-media thickness Meta-analysis
分类号:
R181.23; R543.5; R972.6
文献标志码:
A
摘要:

目的      探讨瑞舒伐他汀强化治疗(20 mg,qd)和常规治疗(10 mg,qd)对国人颈动脉粥样硬化斑块的影响,寻找适合中国人的瑞舒伐他汀剂量。      方法      计算机检索2007-2015年PubMed、Medline、EMBASE、中国知网(CNKI)、维普中文科技期刊和中国生物医学文献数据库等关于在颈动脉粥样硬化患者中应用不同剂量瑞舒伐他汀的随机或半随机对照试验文章,应用系统评价软件Revmen 5.0分析相关指标,并针对不同剂量瑞舒伐他汀对颈动脉内膜厚度(intima-media thickness,IMT)、低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)、高密度脂蛋白胆固醇(high density lipoprotein-cholesterol,HDL-C)和不良反应的影响进行Meta分析。      结果      与10 mg瑞舒伐他汀相比,20 mg 瑞舒伐他汀能更加降低IMT[MD=-0.13,95%CI(-0.17,-0.09)];减少LDL-C水平[MD=-0.50,95%CI(-0.61,-0.39)];提高HDL-C水平[MD=0.13,95%CI(0.09,0.17)];差异均有统计学意义(P<0.000 01)。2组间不良反应发生差异无统计学意义(P>0.05)。      结论      对于颈动脉粥样硬化患者,20 mg/d 瑞舒伐他汀在降低LDL-C、提高HDL-C及减少IMT方面,疗效优于10 mg/d,且安全性相当。

Abstract:

Objective      To determine the effect of rosuvastatin at intensive (20 mg, qd) and regular doses (10 mg, qd) on carotid atherosclerosis in Chinese patients in order to explore a safe and effective dose of rosuvastatin for Chinese population.       Methods      Databases of PubMed, Medline, EMBASE, CNKI, VIP and CBM were searched for randomized controlled trails (RCTs) or semi-randomized controlled trails concerning about the treatment of atherosclerosis by rosuvastatin from the year of 2007 to 2015. The Meta-analysis evaluation software Revman 5.0 was applied to analyzed the obtained studies. The changes of intima-media thickness (IMT), low density lipoprotein-cholesterol (LDL-C) and high density lipoprotein-cholesterol (HDL-C), and side effects after different doses of rosuvastatin treatment were compared in different doses.       Results      Meta-analysis showed that 20 mg rosuvastatin showed stronger reduction in IMT (MD=-0.14, 95%CI: -0.21, -0.07), significant decrease in LDL-C level (MD=-0.53, 95%CI:-0.75, -0.30), and obvious elevation in HDL-C level (MD=0.13, 95%CI: 0.09, 0.17) when compared with 10 mg rosuvastatin (all P<0.000 01). There was no significant difference in the incidence of side effects between the 2 doses.       Conclusion      Rosuvastatin of 20 mg is superior to 10 mg dose in reduce of LDL-C, increase of HDL-C, and decrease of IMT, and the 2 doses are of  comparative similar safety.

参考文献/References:

[1]Nissen S E, Nicholls S J, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis:  the ASTEROID tria1[J]. JAMA, 2006, 295(13): 1556-1565. DOI: 10.1001/jama.295.13.jpc60002
[2]郭远, 宝辉, 李卫, 等. 不同剂量瑞舒伐他汀对老年糖尿病患者颈动脉粥样硬化的影响[J].中国新药杂志, 2011, 20(21):  2123-2126, 2138.
[3]吴晓静, 孙学仁. 瑞舒伐他汀钙强化降脂治疗颈动脉粥样硬化的疗效与安全性[J].山东医药, 2011, 51(9): 83-84. DOI: 10.3969/j.issn.1002-266X.2011.09.048
[4]王尉. 王浩. 陈亭亭. 不同剂量瑞舒伐他汀对颈动脉粥样硬化合并高血脂患者疗效及安全性的对照分析[J]. 中国当代医药, 2012, 19(18): 69-70, 72. DOI: 10.3969/j.issn.1674-4721.2012.18.034
[5]梁文桂. 不同剂量瑞舒伐他汀治疗老年冠心病合并颈动脉粥样硬化斑块的疗效及安全性[J]. 大家健康: 学术版, 2013, 7(8): 78.
[6]颜志钦, 易兴阳, 虞君儒, 等. 瑞舒伐他汀强化降脂对缺血性脑卒中血脂及颈动脉粥样硬化斑块的影响[J]. 中国药物与临床, 2013, 13(11): 1408-1410. DOI: 10.11655/zgywylc2013.11.007
[7]刘玉府, 刘春岭. 瑞舒伐他汀强化降脂治疗对缺血性脑卒中颈动脉粥样斑块的影响[J]. 中国实用神经疾病杂志, 2014, 17(17): 107-108. DOI: 10.3969/j.issn.1673-5110.2014.17.077
[8]邬伟灵. 刍议应用瑞舒伐他汀钙强化降脂治疗颈动脉粥样硬化的临床疗效[J].中外医学研究, 2014, 12(24): 25-26.
[9]王继伟.瑞舒伐他汀钙强化降脂对颈动脉粥样硬化的影响[J].临床合理用药杂志, 2015, 3(3): 5-6.
[10]Cohn J N, Duprez D A, Grandits G A. Arterial elasticity as part of comprehensive assessment of cardiovascular risk and drug treatment[J]. Hypertension, 2005, 46(1): 217-220. DOI: 10.1161/01.HYP.0000165686.50890.c3
[11]Polak J F, Pencina M T, Pencina K M, et al. Carotid-wall intima-media thickness and cardiovascular events[J]. N Engl J Med, 2011, 365(3): 213-221.
[12]Nissen S E. Halting the progression of atherosclerosis with intensive lipid lowering:  results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial[J]. Am J Med, 2005, 118 Suppl 12A:  22-27. DOI: 10.1016/j.amjmed.2005.09.020
[13]Crouse J R 3rd, Raichlen J S, Riley W A, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis:  the METEOR Trial[J]. JAMA, 2007, 297(12):  1344-1353. DOI: 10.1001/jama.297.12.1344
[14]Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome:  a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study)[J]. J Am Coll Cardiol, 2009, 54(4): 293-302. DOI: 10.1016/j.jacc.2009.04.033
[15]Takayama T, Hiro T, Yamagishi M, et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease:  multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)[J]. Circ J, 2009, 73(11): 2110-2117.
[16]Rosenson R S, Otvos J D, Hsia J. Effect of rosuvastatin and atorvastatin on LDL and HDL particle concenltrations in patients with metabolic syndrome:  a randomized, double-blind, controlled study[J]. Diabetes Care, 2009, 32(6):  1087-1091. DOI: 10.2337/dc08-1681
[17]Davidson M H. Rosuvastatin safety:  lessons from the FDA review and post-approval surveillance[J]. Expert Opin Drug Saf, 2004, 3(6): 547-557.
[18]Kargiotis K, Katsiki N, AthyrosV G, et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia:  a preliminary report[J]. Curr Vasc Pharmacol, 2014, 12(3):  505-511.

相似文献/References:

[1]李明,孙守兵,周越,等.去甲肾上腺素诱导人巨噬细胞MMP-9的表达及机制[J].第三军医大学学报,2012,34(17):1758.
 Li Ming,Sun Shoubing,Zhou Yue,et al.Norepinephrine induces expression of matrix metalloproteinase-9 in human macrophages and its mechanisms[J].J Third Mil Med Univ,2012,34(03):1758.
[2]王柯静,程渝,周远大.野马追提取液对动脉粥样硬化家兔炎症反应的防治作用[J].第三军医大学学报,2012,34(18):1853.
 Wang Kejing,Cheng Yu,Zhou Yuanda.Lindley eupatorium herb extract prevents and attenuates vascular inflammation reaction in atherosclerosis rabbits[J].J Third Mil Med Univ,2012,34(03):1853.
[3]蒙颖,徐芳,王志禄,等.罗格列酮对泡沫细胞中胆固醇贮存与运输相关蛋白ACAT-1、ABCA-1表达的影响[J].第三军医大学学报,2012,34(22):2288.
 Meng Ying,Xu Fang,Wang Zhilu,et al.Effect of rosiglitazone on expression of acyl-coenzyme A cholesterol acyltransferase 1 and ATP-binding cassette transporter A1 in foam cells[J].J Third Mil Med Univ,2012,34(03):2288.
[4]黄朝晖,吴雄飞,赵洪雯,等.ApoE-/-小鼠肾动脉狭窄及肾损害特点观察[J].第三军医大学学报,2007,29(19):1844.
 HUANG Zhao-hui,WU Xiong-fei,ZHAO Hong-wen,et al.Atherosclerotic renal artery stenosis and renal injury in apolipoprotein E knockout mouse[J].J Third Mil Med Univ,2007,29(03):1844.
[5]彭丹丹,李志梁.冠状动脉粥样硬化性心脏病患者单核细胞CX3CR1表达的研究[J].第三军医大学学报,2008,30(06):546.
 PENG Dan-dan,LI Zhi-liang.CX3CR1 expressions in monocytes from patients with coronary heart diseases[J].J Third Mil Med Univ,2008,30(03):546.
[6]李骊华,雷寒.不同剂量厄贝沙坦对兔主动脉粥样硬化中环氧合酶2的影响[J].第三军医大学学报,2008,30(10):917.
 LI Li-hua,LEI Han.Effect of Irbesartan on cyclooxygenase-2 in aortic atherosclerotic lesion in rabbits[J].J Third Mil Med Univ,2008,30(03):917.
[7]申丽丽,彭家和,刘红,等.法尼酯X受体对脂肪酸合酶表达的影响[J].第三军医大学学报,2007,29(22):2142.
 SHEN Li-li,PENG Jia-he,LIU Hong,et al.Effects of farnesoid X receptor on expression of fatty acid synthetase in HepG2 cells[J].J Third Mil Med Univ,2007,29(03):2142.
[8]李琴山,刘洋,冯赞杰,等.单核细胞趋化蛋白-1对人脐静脉内皮细胞凋亡的影响[J].第三军医大学学报,2007,29(17):1682.
 LI Qin-shan,LIU Yang,FENG Zan-jie,et al.Monocyte chemotactic protein-1 induces the apoptosis of human umbilical vein endothelial cells[J].J Third Mil Med Univ,2007,29(03):1682.
[9]聂永梅,陈槐卿,成敏,等.兔动脉粥样硬化斑块处单核细胞趋化蛋白-1的表达[J].第三军医大学学报,2006,28(15):1566.
[10]胡厚源,颜伟,周林.肝X受体及其抗动脉粥样硬化作用的研究进展[J].第三军医大学学报,2006,28(12):1354.

更新日期/Last Update: 2016-01-27